ACHV

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2008, for OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.). The Company is a biopharmaceutical enterprise focused on developing cancer therapies, specifically targeting treatment resistance. The reporting period is significantly impacted by a reverse takeover completed on August 21, 2008, where Sonus acquired OncoGenex Technologies Inc. (OncoGenex Technologies). For accounting purposes, OncoGenex Technologies is deemed the acquirer. Consequently, the consolidated results include OncoGenex Technologies' operations for the full nine months of 2008 and Sonus' operations only from the transaction date.

Key Financial Metrics

Note: The Net Income for the three and nine months ended September 30, 2008, is primarily driven by a non-cash extraordinary gain of $4.43 million resulting from "negative goodwill" in the reverse takeover transaction. Excluding this gain, the Company reported a loss attributable to common shareholders of $(1.22 million) for the nine-month period.

Material Changes vs. Prior Period

• Balance Sheet Transformation: Total assets increased from $7.35 million (Dec 31, 2007) to $20.25 million (Sep 30, 2008), driven by the acquisition of Sonus' cash ($5.46 million) and marketable securities ($14.81 million). Total liabilities decreased significantly from $45.57 million to $4.77 million due to the extinguishment of convertible debentures and preferred shares upon the transaction.
• Equity Position: Shareholders' equity shifted from a deficiency of $(38.22 million) at year-end 2007 to a positive $15.48 million, reflecting the capital structure changes from the reverse acquisition.
• Expense Trends: Research and Development (R&D) expenses increased to $3.62 million for the nine months ended Sep 30, 2008, compared to $3.08 million in the prior year, largely due to the inclusion of Sonus' facility costs and employee expenses post-merger. General and Administrative (G&A) expenses decreased to $2.24 million from $2.71 million, attributed to lower financing costs in 2008 compared to IPO-related costs in 2007.
• Tax Recovery: The Company recorded an income tax recovery of $2.10 million for the nine-month period, primarily due to the reversal of a $2.63 million liability related to Canadian Part VI.1 taxes on preferred shares, which were eliminated in the transaction.

Guidance, Outlook, and Risks

• Capital Requirements: Management states that current cash and short-term investments ($17.2 million aggregate) are sufficient to fund operations through 2009. However, additional funding is explicitly required to initiate planned Phase 3 clinical trials for the lead candidate, OGX-011. The Company may seek funding through equity/debt offerings or partnerships.
• Clinical Progress:
  • OGX-011: The FDA agreed that "durable pain palliation" is an acceptable endpoint for a Phase 3 trial in hormone refractory prostate cancer (HRPC). The Company plans to submit a protocol for a Special Protocol Assessment (SPA).
  • OGX-427 & SN2310: Both are in Phase 1 trials. SN2310 enrollment is complete; OGX-427 enrollment is ongoing.
• Restructuring: Following the merger, the Company reduced its workforce by approximately 49% to preserve cash. Severance liabilities of approximately $2.75 million were recognized as part of the purchase price allocation.
• Key Risks:
  • Financing Risk: Failure to secure additional capital could force the curtailment of development activities.
  • Regulatory Risk: No assurance that product candidates will receive FDA approval or that clinical trials will succeed.
  • Lease Obligations: The Company faces significant lease commitments for excess office space in Bothell, Washington, with a recorded liability of $2.04 million. There is uncertainty regarding the ability to sublease or exit this space on favorable terms.

Investor Verification Checklist

• Extraordinary Gain Validity: Verify the finalization of the purchase price allocation and the sustainability of the $4.43 million extraordinary gain recognized from negative goodwill.
• Liquidity Runway: Confirm the sufficiency of the $17.2 million cash position to fund operations through 2009 without immediate dilution or debt issuance.
• Lease Liability Resolution: Monitor progress on subleasing or exiting the excess Bothell, Washington facility to avoid ongoing cash drain.
• Phase 3 Funding: Assess the timeline and terms for securing the additional capital required to launch the Phase 3 trial for OGX-011.
• Escrow Milestones: Track the release of the 1.39 million shares held in escrow, which are contingent on clinical milestones and stock price performance.